Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00992446
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT00983268
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Gynecologic Oncology Associates
- Target Recruit Count
- 18
- Registration Number
- NCT00976183
- Locations
- 🇺🇸
Gynecologic Oncology Associates, Newport Beach, California, United States
Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-09-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 83
- Registration Number
- NCT00972478
- Locations
- 🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸Mount Carmel Health Center West, Columbus, Ohio, United States
🇺🇸Doctors Hospital, Columbus, Ohio, United States
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 11
- Registration Number
- NCT00958074
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas
- Conditions
- Interventions
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT00948688
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 110
- Registration Number
- NCT00948064
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 17
- Registration Number
- NCT00946673
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 58
- Registration Number
- NCT00942266
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT00937495
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.